Literature DB >> 10524938

Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.

T Burchardt1, M Burchardt, M W Chen, Y Cao, A de la Taille, A Shabsigh, O Hayek, T Dorai, R Buttyan.   

Abstract

PURPOSE: To better understand the source of neuroendocrine cells associated with human prostate cancer progression, we studied the ability of a cultured prostate cancer cell line, LNCaP, to transdifferentiate into neuroendocrine-like cells in vitro and in vivo.
MATERIALS AND METHODS: Cyclic AMP concentrations were measured in extracts of LNCaP cells cultured in the presence of normal or hormone-deficient medium (containing charcoal-stripped serum) with the use of an immunoassay. Quantitative RT-PCR procedures were used to determine whether hormone depletion affects TGF-beta2 mRNA expression. Western blotting procedures (for neuron specific enolase [NSE]) were used to determine whether TGF-beta2 supplementation or antibody neutralization might affect the ability of cultured LNCaP cells to transdifferentiate to neuroendocrine-like cells. Finally, tumors formed from LNCaP cells xenografted into male nude mice were evaluated for the presence of neuroendocrine cells (prior and subsequent to castration of the host mouse) using an immunohistochemical stain for chromogranin A.
RESULTS: LNCaP cells cultured in a hormone-deficient medium have a mean 9-fold increase in cyclic AMP (p = 0.02) and a significant decline in the expression of TGF-beta2 mRNA when compared with cells grown in normal medium. Supplementation or depletion of TGF-beta2 did not affect the neuroendocrine conversion of LNCaP cells as assessed by NSE expression patterns. LNCaP tumors growing in castrated male nude mice were found to have significantly increased numbers of chromogranin A positive neuroendocrine cells (46/high powered field) when compared with tumors growing in intact male mice (3/high powered field) (p = 0.0038).
CONCLUSIONS: Exposure of LNCaP cells to a hormone deficient medium drastically increased cyclic AMP production and this may identify the biochemical pathway through which hormone depletion induces a neuroendocrine conversion of prostate cancer cells. Hormone depletion also reduced TGF-beta2 mRNA expression and this finding was consistent with our inability to demonstrate any effect of TGF-beta2 on neuroendocrine conversion in vitro. Finally, our demonstration of increased neuroendocrine cells found in LNCaP tumors growing in castrated immunodeficient mice suggests that the neuroendocrine cells associated with advanced human prostate tumors in vivo, arise from prostate cancer cells through the transdifferentiation process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524938

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  58 in total

Review 1.  Neuroendocrine differentiation: The mysterious fellow of colorectal cancer.

Authors:  Britta Kleist; Micaela Poetsch
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Neuroendocrine differentiation of prostate cancer.

Authors:  Zhen Li; Clark J Chen; Jason K Wang; Elaine Hsia; Wei Li; Jill Squires; Yin Sun; Jiaoti Huang
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

4.  Neuronal Trans-Differentiation in Prostate Cancer Cells.

Authors:  Andrew Farach; Yi Ding; MinJae Lee; Chad Creighton; Nikki A Delk; Michael Ittmann; Brian Miles; David Rowley; Mary C Farach-Carson; Gustavo E Ayala
Journal:  Prostate       Date:  2016-07-12       Impact factor: 4.104

5.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

6.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

7.  Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.

Authors:  Pinar Uysal-Onganer; Yoshiaki Kawano; Mercedes Caro; Marjorie M Walker; Soraya Diez; R Siobhan Darrington; Jonathan Waxman; Robert M Kypta
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

Review 8.  The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.

Authors:  Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Oncotarget       Date:  2010-09

9.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

10.  Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.

Authors:  S Terry; G Ploussard; Y Allory; N Nicolaiew; F Boissière-Michot; P Maillé; L Kheuang; E Coppolani; A Ali; F Bibeau; S Culine; R Buttyan; A de la Taille; F Vacherot
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.